| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6094011 | Gastroenterology | 2014 | 18 Pages |
Abstract
In treatment-experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated. ClinicalTrials.gov number: NCT00980330.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Stefan Zeuzem, Thomas Berg, Edward Gane, Peter Ferenci, Graham R. Foster, Michael W. Fried, Christophe Hezode, Gideon M. Hirschfield, Ira Jacobson, Igor Nikitin, Paul J. Pockros, Fred Poordad, Jane Scott, Oliver Lenz, Monika Peeters, Vanitha Sekar,